NICE backs restricted use of Ondexxya
Funding backed for reversal of gastrointestinal bleeds but not for intracranial haemorrhage
Read More
Tag: factor Xa inhibitor
US approval for Portola’s BevyxXa
Portola Pharmaceuticals’ BevyxXa has been cleared by the US Food and Drug Administration for preventing blood clots in hospitalised patients.
Read More
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
